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A patient with chronic moderate neutropenia, acute hemolysis,
and pyrexia was found to be infected with a novel hemoplasma
species. A clinical response to doxycyline was noted, and
moxiﬂoxacin was added subsequently to aid infection clear-
ance. This represents the ﬁrst report of hemolysis in associa-
tion with conﬁrmed hemoplasma infection in a human.
A 62-year-old white woman from Devon, England, presented with
a 3-week history of pyrexia, abdominal pain, joint pain, weight
loss, and night sweats, starting when she returned home from
vacation in Australia and Singapore. In Australia she had swum in
af r e s h w a t e rt r o p i c a lp o n da n dh a df e dk a n g a r o o sw i t ho t h e r
tourists. She recalled no tick, insect, or animal bites and kept a dog
at home. She had a 3-year history of moderate neutropenia (cell
count, 0.7–1.2 3 10
9cells/L) and distal symmetrical polyarthralgia
b u tw a so t h e r w i s eﬁ ta n dw e l l .
On examination she was pyrexial (temperature, 39.4C)
with hepatosplenomegaly. Full blood count showed anemia
(hemoglobin concentration, 97 g/L), a reduced white blood
cell (WBC) count (WBC count, 1.8 3 10
9 cells/L; neutrophil
count, 0.5 3 10
9 cells/L), and thrombocytopenia (platelet
count, 81 3 10
9 cells/L). A direct antiglobulin (Coombs’) test
was strongly positive for immunoglobulin G (IgG) and
complement C3d, and low haptoglobin concentrations
(,0.06 g/L; reference interval, 0.3–2.0 g/L) were found, con-
ﬁrming hemolytic anemia. A clotting screen was within the
reference interval, and no hemoglobinuria was detected. The
C-reactive protein (CRP) level (94 mg/L; reference interval,
,5 mg/L) and lactate dehydrogenase level (794 U/L; reference
interval, 240–480 U/L) were raised. Liver and renal parameters
were within the reference intervals except for a mildly elevated
aspartate transaminase level (43 U/L; reference interval, 0–31 U/L).
Serological tests for hepatitis B and C virus were negative. Anti-
nuclear and smooth muscle antibody tests were positive (concen-
trations, 1:160 and 1:80, respectively), whereas mitochondrial
antibody testing was negative. Blood smears showed no evidence
of micro-organisms. Blood cultures were negative and a trans-
thoracic echocardiogram was normal.
Ultrasound-guidedliverbiopsytoinvestigatepersistentpyrexia
andhepatosplenomegalyresultedinahepaticarterialbleed,which
was refractory to radiological embolization and required lapa-
rotomytoachievehemostasis.Liver histology revealed no speciﬁc
etiological features. Continuing postoperative pyrexia was then
attributed to infection of a hepatic subcapsular hematoma, but
was refractory to co-amoxiclav and metronidazole, and sub-
sequently to vancomycin and piperacillin-tazobactam, given to
broadencoverage against possible infection withhospital-acquired
pathogens.
During the postoperative period the patient developed renal
failure. Renal biopsy revealed acute tubular interstitial nephritis
with focal granuloma formation and was negative for acid-fast
bacilli and fungi. Tests for antineutrophil cytoplasmic antibody
(concentration, 1:1280) and proteinase 3 antibody (weak) were
positive. Systemic lupus erythematosus was considered, but in-
sufﬁcient features were present to make a diagnosis; although
the patient was positive for antinuclear antibody (ANA), cyto-
penias, and arthralgia, both double-stranded DNA and lupus
anticoagulant tests were negative, and there was no serositis, oral
ulcers, photosensitivity, pre-existing renal disorder, neurological
d i s o r d e r ,m a l a r ,o rd i s c o i dr a s h .N o n e t h e l e s s ,p r e d n i s o l o n e( 4 0m g
once daily) was started in view of possible sarcoidosis or other
immune disorder. Piperacillin-tazobactam and doxycycline
(100 mg once daily orally) for 5 days were also started at this
time as empirical treatment for hospital-acquired pneumonia,
diagnosed due to fever, inspiratory crepitations, and shadowing
in the right base on chest radiography. Blood and sputum
cultures were negative. The pyrexia resolved within 24 hours
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count, and no immediate need for further transfusion over 5
days, the patient was discharged and continued taking pred-
nisolone.
Twenty-onedaysaftercessationofthepiperacillin-tazobactam
and doxycycline, the patient represented with light-headedness,
nausea, petechiae on the legs, and pyrexia. Anemia (hemoglobin
concentration, 89 g/L) and thrombocytopenia (platelet count,
313 10
9cells/L)werepresentbuttheWBCcountwaswithinthe
reference interval (WBC count, 7.3 3 10
9 cells/L; neutrophil
count, 4.3 3 10
9 cells/L). The prednisolone dose was increased
(60 mg once daily) and azathioprine (50 mg once daily) was
initiated, but continued hemolysis (positive Coombs’ test posi-
tive and low haptoglobin level) necessitated multiple trans-
fusions (14 units over 14 days). Treatment with IgG (1 g/kg) was
ineffective. Bone marrow cellularity was normal with brown
pigment (likely hemosiderin) and an absence of hemophagocy-
tosis. A Gallium scan showed prominent tracer uptake through-
out the axial skeleton but no hepatosplenic uptake. Magnetic
resonance imaging showed diffuse low signal intensity of the
bone marrow on T1-weighted images, suggesting myeloprolif-
erative disease. A further bone marrow analysis revealed hemo-
phagocytosis only.Testingforacid-fastbacilli,Epstein Barrvirus,
cytomegalovirus, and Leishmania species (spp) by means of
polymerase chain reaction (PCR) and serology, were all negative.
Ongoing hemolysis and pyrexia with a temperature of up to
40C resulted in initiation of doxycycline treatment (100 mg
twice daily orally), this time as monotherapy for possible
nonculturable intracellular pathogens. After starting this
treatment, the pyrexia resolved within 24 hours, the throm-
bocytopenia resolved within 4 days, and the hemoglobin con-
centration (112 g/L) was within the reference interval within 1
week. Bone marrow, collected during the clinical relapse, was
subjected to eubacterial 16S ribosomal RNA (rRNA) gene PCR
to identify any yet unidentiﬁed bacterial infections. Sequence
data of an ampliﬁed PCR product showed greatest identity
(92.1% and 89.9%, respectively) to the veterinary hemotropic
mycoplasma species (trivial name hemoplasma) Mycoplasma
haemomuris (GenBank no. U82963) and ‘‘Candidatus Myco-
plasma turicensis’’ (GenBank no. DQ464423).
On the basis of treatment recommendations for veterinary
hemoplasmosis, doxycycline was continued for 3 weeks. The pa-
tient remained well during this time, and the azathioprine was
stopped and the prednisolone gradually withdrawn. However,
17 days after stopping doxycycline the patient deteriorated again
with pyrexia,sweats,vomiting,and shortnessof breath. Hemolysis
was conﬁrmed as before with painful splenomegaly. Repeat bone
marrow samples were collected, which showed macrophage in-
clusions consistent with hemolysis. Doxycycline (100 mg twice
daily orally) was restarted and the patient again improved im-
mediately; temperature normalized within 24 hours and the he-
mogram normalized within a week. The bone marrow was
negative for Mycoplasma and Ureaplasma spp by culture, but was
again positive for hemoplasma DNA, this time demonstrated by
panhemoplasma quantitative PCR (qPCR) [1]. PCR, sequencing,
and phylogeny of the near-complete 16S rRNA and partial RNase
Figure 1. Phylogenetic analysis of nearly complete 16S ribosomal RNA (rRNA) gene sequences for the newly described hemoplasma species (shown in
boldface) and other available hemoplasma species. The tree was constructed by the neighbor-joining method. Evolutionary distances are to the scales
shown. The data set was resampled 1000 times to generate bootstrap percentage values, and values of .50% are given at the nodes of the tree. The
phylogenetic tree was rooted to Clostridium innocuum (GenBank no. M23732). GenBank accession numbers are shown for all sequences.
aThe bovine
hemoplasma ''Candidatus Mycoplasma haemobovis'' 16S rRNA gene sequence (GenBank no. EF424082) shares 99.3% identity with the 1204 base pairs
of the 16S rRNA gene sequence of the buffalo hemoplasma ''Candidatus Mycoplasma haemobos'' (GenBank no. EU367965).
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the hemoplasma species to be novel (Figures 1 and 2).
Doxycycline treatment was continued and qPCR regularly
used to monitor the amount of hemoplasma DNA in the blood
(Table 1). Because blood was still qPCR positive after 8 weeks of
doxycycline (albeit at low levels), moxiﬂoxacin (400 mg once
daily) was added as a quinolone with excellent activity against
mycoplasmas. The patient remained taking dual doxycycline
and moxiﬂoxacin treatment for 6 months, during which time
she had neutropenia (cell count, 0.6–1.6 3 10
9 cells/L) with
normal hemoglobin concentration and reticulocyte count; low
levels of hemoplasma DNA were intermittently detected by the
panhemoplasma qPCR. Treatment was then stopped and the
patient was monitored by means of blood panhemoplasma
qPCR testing, which was negative throughout follow-up. The
posttreatment ANA concentration was 1:80, ds DNA antibody
testing was negative, and the CRP level was normal. One year
following cessation of treatment the patient remains well, other
than ongoing polyarthralgia and low WBC count. Blood from
the patient’s husband and pet dog were both negative for
hemoplasma DNA by qPCR.
During the prolonged hospitalization, serial blood and urine
cultures were negative. Serological tests for human immunode-
ﬁciency virus (HIV), Toxoplasma gondii IgM, Coxiella burnetii,
Brucella abortus, Burkholderia pseudomallei, Anaplasma phag-
ocytophilum, Ehrlichia chaffeensis, Borrelia burgdorferi, Tropheryma
whipplei, Histoplasma capsulatum, Rickettsia conorii, Rickettsia
typhi, Rickettsia felis, and Francisella tularensis were all negative.
Serological tests for Chlamydophila psittaci (concentration,
1:128) and Chlamydophila pneumoniae (concentration, 1:1500)
were positive but remained unchanged on repeat sampling and
were assumed to represent previous Chlamydophila infection.
In particular, Bartonella henselae, Bartonella quintana, Barto-
nella genus-speciﬁc PCR, Mycoplasma pneumoniae serology,
and mycoplasma agglutination tests were all negative.
Immune causes of the neutropenia in the years preceding
presentation were considered. There were ﬂuctuating titers of
ANA levels (1:80–1:160), but the anti–ds DNA tests were con-
sistently negative from 4 years prior to presentation and
throughout the current febrile illness. Although the patient was
neutropenic on initial presentation, during her hospital stay, her
WBC count increased to within the reference range and, on
occasions, above the reference range (as did the neutrophil
count) until discharge. During and after treatment for hemo-
plasma infection, the WBC and neutrophil counts decreased to
levels seen before infection.
Discussion
This case represents the ﬁrst report of a novel hemoplasma
species in a human in association with doxycycline-responsive
pyrexia, hemolytic anemia, and a history of chronic moderate
neutropenia. The name ‘‘Candidatus Mycoplasma haemoho-
minis’’ is proposed for this novel organism should further
Figure 2. Phylogenetic analysis of partial RNase P RNA gene (rnp) gene sequences for the newly described hemoplasma species (shown in boldface)
and other available hemoplasma species. The phylogenetic tree was rooted to Clostridium innocuum (GenBank no. U64878). The tree was constructed by
the neighbor-joining method. Evolutionary distances are to the scales shown. GenBank accession numbers are shown for all sequences. The data set was
resampled 1000 times to generate bootstrap percentage values, and values of .50% are given at the nodes of the tree.
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first in describing human infection with a novel hemoplasma
species that is distinct from described veterinary hemoplasma
species, second in associating human hemoplasma infection
with clinically signiﬁcant hemolysis, and third in the use of
qPCR to quantify hemoplasma DNA in human diagnostic
samples and thus monitor response to treatment. Diagnosis of
hemoplasma infection in this patient was based on PCR analysis
of bone marrow–derived DNA, but peripheral blood samples
could have been an alternative source of DNA for diagnosis, as
performed in veterinary practice [2].
Hemoplasmas infect many mammalian species and can induce
life-threatening hemolytic anemia [2]. Human hemoplasma-like
infections have been reported occasionally in immunocompro-
mised patients by means of cytological diagnosis, which is
known to be very unreliable [1, 3]. PCR methods are now used
to investigate human hemoplasma infections. Limited human
epidemiological studies have failed to detect infections [1, 4].
Although human hemoplasma infections have been reported in
China [5, 6], these descriptions have not described clinical dis-
ease, PCR methodology, or infecting species, making in-
terpretation difﬁcult. Other studies have described the presence
of existing veterinary hemoplasma species DNA in humans:
Mycoplasma suis [7, 8], Mycoplasma haemofelis and/or Myco-
plasma haemocanis [9, 10], and Mycoplasma ovis [11]. However,
any association between hemoplasma infection and clinical signs
in these reports is difﬁcult to ascertain due to either lack of
clinical information provided [7, 8, 10] or concurrent B. henselae
infection [9, 11]. It is unlikely that co-infection with Bartonella
spp was present in this case due to the negative serological and
PCR results for Bartonella s p po b t a i n e da n dt h ef a c tt h a to n l y
hemoplasma DNA was detected by 16S rDNA PCR. It is
possible that the patient’s neutropenia played a role in the
initial development of clinical hemoplasmosis through





absolute no. of hemoplasma copies
per PCR [GAPDH Ct value]
Clinical re ´sume ´
and/or treatment
2 Serum 5.8 x 10
3 [30.1] Pyrexia, pancytopenia,
hepatosplenomegaly
5 Bone marrow 4.9 x 10
6 [21.8]
Pyrexia, hemolysis 5.25 Serum 1.2 x 10
5 [27.8]
6 Serum Not detected [37.5] Doxycycline
Withdrawal of prednisolone
7 Bone marrow












9.5 Blood ,10 [22.1]





12.5 Blood ,10 [23.2]
13 Blood Not detected [24.5]
14.5 Blood Not detected [23.2]
Asymptomatic
14.75 Blood Not detected [24.1]
15 Blood Not detected [21.8]
16 Blood Not detected [26.1]
18 Blood Not detected [22.3]
19 Blood Not detected [23.8]
Abbreviations: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was ampliﬁed as an internal control [1]. The threshold cycle (Ct) number was obtained by
quantitative polymerase chain reaction (qPCR) for the GAPDH internal control. The qPCR results for samples of different origin cannot be directly compared with
each other due to differences in dilution, collection medium, and volume used for DNA extraction. However, the hemoplasma copy numbers shown represent those
present per PCR, which equates to number of copies per 5 lL of blood, bone marrow, or serum, assuming complete efﬁciency of DNA puriﬁcation and PCR
ampliﬁcation. Stored samples were analyzed retrospectively. Because hemoplasma organisms are erythrotropic, PCR analysis of samples containing erythrocytes
(blood and bone marrow) is usually preferred over that of serum samples. However, some serum samples generated positive hemoplasma PCR results in the
current case report. We believe this likely reﬂects the very high numbers of organisms present in the blood at the time of serum preparation, meaning that
detachment of even a small number of organisms from erythrocytes allowed their detection in the serum by PCR.
a Two different preservatives (Tryptic Soya Broth and Viral Transport Media) were used for bone marrow collection, and qPCR was performed on both, giving the
2 results shown.
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infection played a role in causing neutropenia, as evidenced by
the long history of neutropenia prior to any illness and return to
low WBC counts with effective treatment and clearance of in-
fection on speciﬁc qPCR, but this remains a possibility.
The origin of the hemoplasma infection in this patient is not
known. It is possible that it represents a zoonotic infection ac-
quired, for example, from blood-sucking arthropods such as
ticks, ﬂeas, and lice [2] or by direct transmission from another
mammalian host through parenteral or oral inoculation of
blood [3], but no such transmission events were recalled by the
patient before onset of disease. It is possible that this novel
hemoplasma represents a species of which the primary host is
humans. Hemoplasma infections exist in veterinary species in
both the United Kingdom and Australia so transmission could
have occurred before, during, or after the patient’s vacation.
Besides the patient’s husband and pet dog (both of which were
tested for hemoplasma DNA) there was no other signiﬁcant
animal or mammal contact reported.
As described elsewhere for veterinary hemoplasma in-
fections [3], the patient described here showed a remarkable
clinical response to doxycycline. Subsequently, a 6-month
course of doxycycline and moxiﬂoxacin was associated with
negative qPCR results for hemoplasma DNA, and the patient
then remained qPCR negative following cessation of treat-
ment. The low levels of hemoplasma DNA detected by qPCR
at some time points during doxycycline and moxiﬂoxacin
treatment could reﬂect ampliﬁcation of nonviable hemo-
plasma DNA that had not been cleared from the circulation,
although in animal studies rapid clearance of hemoplasma
DNA from the circulation is usually reported following
effective antibiotic treatment.
In conclusion, hemoplasmosis should be considered as a
differential diagnosis in patients with hemolytic anemia and
pyrexia. PCR testing for hemoplasma DNA should be included
inthe investigationofsuchpatientstoenabletherapiddetection
of this infection, which may be more common than previously
realized.
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